Gabify, a healthtech startup that focuses on neurodevelopmental care for children, has raised US$175,000 in its pre-seed funding round led by Inflection Point Ventures.
The company also received ₹25 lakh under the Nidhi Seed Support Scheme from GHRTBI.
It will use the funds to test its solutions, improve its technology, and grow its team. Gabify also plans to expand its services through business partnerships, direct customers, and CSR programs, with a goal to reach one million children by 2028.
“Working with Inflection Point Ventures has been a deeply collaborative experience. Beyond capital, IPV brings strategic insight, credibility, and a strong founder-first mindset. Our goal with Gabify is to ensure that no child is left behind simply due to delayed diagnosis or lack of access. We are building technology that empowers clinicians, supports parents, and gives every child a fair chance at early intervention and a better future,” said Sahil Chopra, Founder & CEO, Gabify.
Ankur Mittal, Co-founder, Inflection Point Ventures, said, “Addressing neurodevelopmental challenges at an early stage plays a critical role in shaping a child’s future, yet it remains one of the most underserved areas in the healthcare ecosystem. Gabify is tackling this gap through a strong blend of clinical validation and AI-led innovation, enabling faster and more accurate identification of developmental conditions.”
“Their approach has the potential to significantly reduce diagnosis timelines, improve intervention outcomes, and expand access to quality care for families and clinicians alike. At Inflection Point Ventures, we are excited to support Gabify as they work toward transforming early detection and intervention pathways through scalable, technology-driven solutions, both in India and globally. We look forward to leveraging our network and strategic expertise to help the company accelerate its growth journey.”
Founded in 2023 by Sahil Chopra, Prachi Sood, and Vasyl Leshchuk, Gabify is creating an AI-powered platform to help with the early detection and management of speech and neurodevelopmental disorders such as autism and ADHD.
The platform uses two types of AI—one for voice and one for visual analysis. It studies things like how a child speaks, their facial expressions, and their behavior using medically approved methods. It also involves human experts to check and confirm the results for better accuracy.
Read More- Multiplier Acquires Oxygen Advisors in Strategic Deal
